BR9913722A - Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo - Google Patents

Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo

Info

Publication number
BR9913722A
BR9913722A BR9913722-4A BR9913722A BR9913722A BR 9913722 A BR9913722 A BR 9913722A BR 9913722 A BR9913722 A BR 9913722A BR 9913722 A BR9913722 A BR 9913722A
Authority
BR
Brazil
Prior art keywords
active agent
human patient
delivering
lung
lungs
Prior art date
Application number
BR9913722-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Clarke
Mei-Chang Kuo
Cecily Lavor
Barry John Aldous
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of BR9913722A publication Critical patent/BR9913722A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
BR9913722-4A 1998-09-14 1999-09-13 Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo BR9913722A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14
PCT/US1999/021109 WO2000015262A1 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Publications (1)

Publication Number Publication Date
BR9913722A true BR9913722A (pt) 2001-05-29

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913722-4A BR9913722A (pt) 1998-09-14 1999-09-13 Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo

Country Status (44)

Country Link
EP (1) EP1117442A1 (is)
JP (1) JP2002524535A (is)
KR (1) KR20010075063A (is)
CN (1) CN1317977A (is)
AP (1) AP1374A (is)
AR (1) AR022090A1 (is)
AU (1) AU753014B2 (is)
BG (1) BG105430A (is)
BR (1) BR9913722A (is)
CA (1) CA2343920A1 (is)
CO (1) CO5130023A1 (is)
CZ (1) CZ2001829A3 (is)
DZ (1) DZ2892A1 (is)
EA (1) EA003476B1 (is)
EE (1) EE200100151A (is)
GE (1) GEP20043257B (is)
GT (1) GT199900156A (is)
HK (1) HK1042231A1 (is)
HN (1) HN1999000159A (is)
HR (1) HRP20010189A2 (is)
HU (1) HUP0103837A3 (is)
ID (1) ID28845A (is)
IL (2) IL141562A0 (is)
IS (1) IS5878A (is)
LT (1) LT4897B (is)
LV (1) LV12658B (is)
MA (1) MA25590A1 (is)
MY (1) MY129282A (is)
NO (1) NO20011251L (is)
NZ (1) NZ510168A (is)
OA (1) OA11781A (is)
PA (1) PA8481901A1 (is)
PE (1) PE20001061A1 (is)
PL (1) PL195574B1 (is)
SA (1) SA99200718B1 (is)
SK (1) SK3442001A3 (is)
TN (1) TNSN99173A1 (is)
TR (1) TR200101182T2 (is)
TW (1) TWI226248B (is)
UA (1) UA76085C2 (is)
UY (1) UY25711A1 (is)
WO (1) WO2000015262A1 (is)
YU (1) YU24201A (is)
ZA (1) ZA200101995B (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7351844B2 (en) 2002-02-25 2008-04-01 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
ES2280835T3 (es) * 2002-12-19 2007-09-16 Pharmacia Corporation Formulacion no higroscopica que comprende un farmaco higroscopico.
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2007534693A (ja) 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤
JP2008531582A (ja) 2005-02-24 2008-08-14 ディフュージョン・ファーマシューティカルズ・エルエルシー トランスカロテノイド、それらの合成、配合、および使用
RU2007137121A (ru) * 2005-03-09 2009-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Частица и препарат, содержащий указанную частицу
HUE035181T2 (hu) 2005-10-26 2018-05-02 Cydex Pharmaceuticals Inc Szulfoalkil-éter-ciklodextrin kompozíciók és eljárások elõállításukra
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
KR20090081407A (ko) * 2006-10-25 2009-07-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 고결 방지 과립상 제제
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
EA200970944A1 (ru) 2007-04-13 2010-06-30 Диффьюжн Фармасьютикалз Ллс Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
MX2010004803A (es) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc Una nueva clase de composiciones terapeuticas que mejoran la difusion de moleculas pequeñas.
TR201802619T4 (tr) * 2009-05-20 2018-03-21 Aeras Kararlı, sprey ile kurutulmuş, immunojen, viral bileşimler.
CA2765697C (en) 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
IN2014MN02359A (is) 2012-05-03 2015-08-14 Janssen R & D Ireland
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
HUP0103837A2 (hu) 2002-05-29
PL195574B1 (pl) 2007-10-31
CN1317977A (zh) 2001-10-17
ZA200101995B (en) 2002-03-11
NO20011251D0 (no) 2001-03-13
TWI226248B (en) 2005-01-11
LT2001021A (en) 2001-11-26
NZ510168A (en) 2003-09-26
CO5130023A1 (es) 2002-02-27
ID28845A (id) 2001-07-05
IL141562A (en) 2007-07-24
AU753014B2 (en) 2002-10-03
SA99200718B1 (ar) 2006-11-04
CZ2001829A3 (cs) 2001-09-12
HK1042231A1 (zh) 2002-08-09
PE20001061A1 (es) 2000-10-08
JP2002524535A (ja) 2002-08-06
HRP20010189A2 (en) 2005-04-30
EP1117442A1 (en) 2001-07-25
IS5878A (is) 2001-03-05
CA2343920A1 (en) 2000-03-23
AP1374A (en) 2005-02-28
AR022090A1 (es) 2002-09-04
PA8481901A1 (es) 2002-04-25
DZ2892A1 (fr) 2003-12-15
MY129282A (en) 2007-03-30
EA200100300A1 (ru) 2001-10-22
GEP20043257B (en) 2004-06-25
KR20010075063A (ko) 2001-08-09
HUP0103837A3 (en) 2002-11-28
OA11781A (en) 2005-07-26
AP2001002093A0 (en) 2001-03-31
AU6039799A (en) 2000-04-03
YU24201A (sh) 2003-08-29
EE200100151A (et) 2002-06-17
HN1999000159A (es) 1999-11-11
UY25711A1 (es) 1999-11-17
LV12658A (lv) 2001-05-20
SK3442001A3 (en) 2001-11-06
PL346768A1 (en) 2002-02-25
MA25590A1 (fr) 2002-12-31
TR200101182T2 (tr) 2001-09-21
LV12658B (lv) 2001-09-20
GT199900156A (es) 2001-03-07
TNSN99173A1 (fr) 2005-11-10
IL141562A0 (en) 2002-03-10
NO20011251L (no) 2001-04-17
EA003476B1 (ru) 2003-06-26
WO2000015262A1 (en) 2000-03-23
BG105430A (en) 2001-12-29
LT4897B (lt) 2002-02-25
UA76085C2 (en) 2006-07-17

Similar Documents

Publication Publication Date Title
BR9913722A (pt) Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo
Hickey et al. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives
NO20025873D0 (no) Meget effektiv levering av en stor terapeutisk mengde aerosol
DE69936268D1 (de) Verbesserte pulverformulierungen zur inhalation
PT1061901E (pt) Inalador de nicotina
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
DE59914603D1 (de) Multidosis-Trockenpulverinhalator mit Pulverreservoir
HUP0301518A2 (hu) Légzési rendellenességek kezelésére alkalmas száraz porkészítmény és eljárás az előállítására
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
Ruijgrok et al. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats
DE69806362D1 (de) Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
Ferron Aerosol properties and lung deposition
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
EE04038B1 (et) Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
BR0013250A (pt) Formulações de suspensão aquosa ectoparasiticida de espinosinas
JPS60215092A (ja) 人体塗布用粉末エアゾ−ル組成物
Miller et al. Inhibition of hamster buccal pouch carcinogenesis by green coffee beans
EE03950B1 (et) Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine
CA2265198A1 (en) Method of producing a nicotine medicament and a medicament made by the method
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法
TH59260B (th) การให้สารออกฤทธิ์ที่ได้รับการทำเป็นแอโรซอล
JP2000086480A (ja) 荒れ肌改善化粧料
JP2004002244A (ja) イヌまたはネコ体表の発毛・育毛方法
TH59260A3 (th) การให้สารออกฤทธิ์ที่ได้รับการทำเป็นแอโรซอล

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.